Katarzyna Błochowiak1, Jerzy Sokalski2, Ewelina Golusińska2, Dorota Trzybulska3, Henryk Witmanowski4, Magdalena Bodnar5,6, Andrzej Marszałek5,7. 1. Department of Oral Surgery, Poznan University of Medical Sciences, Bukowska 70 Street, 60-812, Poznan, Poland. kasia@naszdentysta.com.pl. 2. Department of Oral Surgery, Poznan University of Medical Sciences, Bukowska 70 Street, 60-812, Poznan, Poland. 3. Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Przybyszewskiego 39 Street, 60-356, Poznan, Poland. 4. Department of Plastic, Aesthetic and Reconstructive Surgery, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University of Torun, Sklodowskiej-Curie 9 Street, 85-094, Bydgoszcz, Poland. 5. Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University of Torun, Sklodowskiej-Curie 9 Street, 85-094, Bydgoszcz, Poland. 6. Department of Otolaryngology and Laryngeal Oncology, Poznan University of Medical Sciences, Przybyszewskiego 49 Street, 60-355, Poznan, Poland. 7. Department of Oncologic Pathology and Prophylaxis, Poznan University of Medical Sciences & Greater Poland Cancer Center Poznan, Garbary 15 Street, 61-866, Poznan, Poland.
Abstract
OBJECTIVES: Angiogenesis underlies tumour growth and metastasis through hepatocyte growth factor (HGF), epithelial growth factor (EGF), and vascular endothelial growth factor (VEGF). The aim of this study was to determine the levels of VEGF, EGF, HGF, HGFR (hepatocyte growth factor receptor), and SRSF1 (serine-rich protein splicing factor-1) in patients with parotid gland tumours and in healthy controls via ELISA in parotid saliva. Immunohistochemical expression of anti-angiogenic isoform of VEGF165b subunit, VEGFR1, VEGFR2, and microvessel density (CD34) were assessed in the tumour tissue and in the non-tumorous surrounding margins. MATERIALS AND METHODS: The study included 48 patients with benign and malignant parotid gland tumours and 15 healthy controls. RESULTS: Comparison of VEGF, EGF, and HGF in tumour and non-tumorous tissues showed no significant differences and no correlations with tumour stage. The salivary VEGF concentration was significantly higher in patients with pleomorphic adenoma and Warthin's tumour. No significant correlation was found between expression of VEGF165b and VEGFR2 in tumours and non-tumor surgical margins. CONCLUSIONS: The increased salivary VEGF reflects changes in affected parotid glands, but it cannot be used as a prognostic and differentiative factor for parotid tumours. CLINICAL RELEVANCE: Reciprocal relations between growth factors suggest an overlapping pathway of secretion and activity.
OBJECTIVES: Angiogenesis underlies tumour growth and metastasis through hepatocyte growth factor (HGF), epithelial growth factor (EGF), and vascular endothelial growth factor (VEGF). The aim of this study was to determine the levels of VEGF, EGF, HGF, HGFR (hepatocyte growth factor receptor), and SRSF1 (serine-rich protein splicing factor-1) in patients with parotid gland tumours and in healthy controls via ELISA in parotid saliva. Immunohistochemical expression of anti-angiogenic isoform of VEGF165b subunit, VEGFR1, VEGFR2, and microvessel density (CD34) were assessed in the tumour tissue and in the non-tumorous surrounding margins. MATERIALS AND METHODS: The study included 48 patients with benign and malignant parotid gland tumours and 15 healthy controls. RESULTS: Comparison of VEGF, EGF, and HGF in tumour and non-tumorous tissues showed no significant differences and no correlations with tumour stage. The salivary VEGF concentration was significantly higher in patients with pleomorphic adenoma and Warthin's tumour. No significant correlation was found between expression of VEGF165b and VEGFR2 in tumours and non-tumor surgical margins. CONCLUSIONS: The increased salivary VEGF reflects changes in affected parotid glands, but it cannot be used as a prognostic and differentiative factor for parotid tumours. CLINICAL RELEVANCE: Reciprocal relations between growth factors suggest an overlapping pathway of secretion and activity.
Authors: Anna Krahel; Elzbieta Paszynska; Agnieszka Slopien; Maria Gawriolek; Justyna Otulakowska-Skrzynska; Szymon Rzatowski; Amadeusz Hernik; Tomasz Hanć; Ewa Bryl; Paula Szczesniewska; Karolina Bilska; Joanna Duda; Marta Tyszkiewicz-Nwafor; Monika Dmitrzak-Weglarz Journal: Int J Environ Res Public Health Date: 2021-01-18 Impact factor: 3.390